Genocea Provides Fourth Quarter 2021 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Apple sues OpenAI, two former employees for trade secrets theft
Genocea Biosciences (GNCA) Tops Q4 EPS by 1c
March 10, 2022 7:01 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).
Genoceas existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.
For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.
... More